Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价NT-002胶囊治疗中国慢性肾脏病3期或4期伴维生素D不足的继发性甲状旁腺功能亢进的有效性和安全性的多中心、随机、双盲、安慰剂、平行对照的临床试验
[Translation] A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of NT-002 capsules in the treatment of secondary hyperparathyroidism in Chinese patients with chronic kidney disease stage 3 or 4 and vitamin D insufficiency
主要目的:评估NT-002胶囊治疗CKD 3期或4期伴VDI的SHPT患者的有效性。
次要目的:评估NT-002胶囊治疗CKD 3期或4期伴VDI的SHPT患者的安全性。
[Translation] Primary objective: To evaluate the efficacy of NT-002 capsules in the treatment of SHPT patients with CKD stage 3 or 4 and VDI.
Secondary objective: To evaluate the safety of NT-002 capsules in the treatment of SHPT patients with CKD stage 3 or 4 and VDI.
100 Clinical Results associated with Nianyan Pharmaceutical (Shanghai) Co., Ltd.
0 Patents (Medical) associated with Nianyan Pharmaceutical (Shanghai) Co., Ltd.
100 Deals associated with Nianyan Pharmaceutical (Shanghai) Co., Ltd.
100 Translational Medicine associated with Nianyan Pharmaceutical (Shanghai) Co., Ltd.